<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://bjo.bmj.com">
<title>British Journal of Ophthalmology current issue</title>
<link>http://bjo.bmj.com</link>
<description>British Journal of Ophthalmology RSS feed -- current issue</description>
<prism:coverDisplayDate>Jun  1 2012 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>British Journal of Ophthalmology</prism:publicationName>
<prism:issn>0007-1161</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/i?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/771?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/774?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/776?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/781?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/783?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/788?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/793?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/796?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/801?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/806?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/811?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/816?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/821?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/826?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/832?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/838?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/841?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/846?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/852?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/857?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/862?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/867?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/872?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/877?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/881?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/884?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/890?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/896?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/900?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/905?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/909?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/910-a?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/910-b?rss=1" />
  <rdf:li rdf:resource="http://bjo.bmj.com/cgi/content/short/96/6/911?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://hwmaint.bjo.bmj.com/homepage/BJO_95x60.gif" />
</channel>
<image rdf:about="http://hwmaint.bjo.bmj.com/homepage/BJO_95x60.gif">
<title>British Journal of Ophthalmology</title>
<url>http://hwmaint.bjo.bmj.com/homepage/BJO_95x60.gif</url>
<link>http://bjo.bmj.com</link>
</image>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/i?rss=1">
<title><![CDATA[Highlights from this issue]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/i?rss=1</link>
<description><![CDATA[ <sec><st>200&nbsp;kHz Femto-LASIK</st> <p>von Mohrenfels <I>et al</I> studied in vivo LASIK cuts with a new prototype 200&nbsp;kHz femtosecond laser in 20 eyes (11 patients). In this pilot series, flap creation was possible in each case. The preoperative MRSE improved from&mdash;4.22 D (SD&plusmn;1.22 D) to <b>&ndash;</b>0.15 D (SD&plusmn;0.16 D) 12&nbsp;months after surgery. Eighteen of the 20 treated eyes were within &plusmn;0.5 D and all eyes were within &plusmn;1.0 D of the intended correction. Femto-LASIK with this new laser system showed high levels of safety, stability and efficacy. (<b><I>see page <addart type="iti" doi="10.1136/bjophthalmol-2011-300073">788</addart></I></b>).</p> </sec> <sec><st>The role of OCT in identifying shape and size of idiopathic epiretinal membrane</st> <p>Hajnajeeb <I>et al</I> investigated the role of the preoperative OCT retinal thickness map (RTM) in identifying the shape and the size of the idiopathic epiretinal membrane (iERM) in 15 eyes that underwent vitrectomy with indocyanine green-assisted membrane peeling. Analysis of iERM morphologic characteristics (shape) showed...]]></description>
<dc:creator><![CDATA[Dua, H. S., Singh, A. D.]]></dc:creator>
<dc:date>2012-05-15T13:21:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301961</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301961</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Highlights from this issue]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>At a glance</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>i</prism:startingPage>
<prism:endingPage>i</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/771?rss=1">
<title><![CDATA[Global health for future ophthalmologists--time to address the gaps: a UK perspective]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/771?rss=1</link>
<description><![CDATA[ <sec><st>What is Global Health?</st> <p>Globalisation has created a myriad of unprecedented challenges and opportunities for healthcare systems. For decades, the health systems of wealthier nations have benefited from the migration of healthcare workers from resource-poor areas of the world. This &lsquo;brain drain&rsquo; has had significant effects on the healthcare systems of the countries that these workers have left behind. We have also witnessed the rapid spread of infectious diseases across continents in unexpected ways, most notably with the outbreak of the severe acute respiratory syndrome epidemic. We now see the rise of non-communicable diseases and their risk factors that have spread from wealthier to poorer countries, with a rapid increase in low- and middle-income countries. This led to the United Nations convening a summit on non-communicable diseases in September 2011, providing a unique opportunity to address these global issues at the highest international level.<cross-ref type="bib" refid="b1">1</cross-ref></p> <p>Evidently, nations can...]]></description>
<dc:creator><![CDATA[Malik, A. N. J., Das, A., Hall, J., Crisp, N.]]></dc:creator>
<dc:date>2012-05-15T13:21:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301675</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301675</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Public health, Angle, Intraocular pressure, Vision, Neurology, Glaucoma, Epidemiology]]></dc:subject>
<dc:title><![CDATA[Global health for future ophthalmologists--time to address the gaps: a UK perspective]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Editorials</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>771</prism:startingPage>
<prism:endingPage>773</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/774?rss=1">
<title><![CDATA[The changing spectrum of microbial keratitis: is microsporia increasing as a cause of microbial keratitis or is it a previously unrecognised cause?]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/774?rss=1</link>
<description><![CDATA[ <p>Microbial keratitis is an old disease and is not limited to humans, but we have a unique ability to change its prevalence and epidemiology, unlike other animals.</p> <p>Ten to eight thousand years ago, we were a hunter-gatherer species with an average life span of 20&ndash;30&nbsp;years.<cross-ref type="bib" refid="b1">1</cross-ref> Trauma was likely to be the principal cause of keratitis, with soil-based bacterial and fungal agents the main pathogens. Societies were mostly tribal and contact with other tribal groups was infrequent and often violent.</p> <p>Eight to four thousand years ago as we began congregating in villages and becoming more agrarian, lifespan increased slightly, and community organisation improved. The domestication of animals contributed to these improvements. Animals would be valuable, and value would mean close contact. Domesticated animals would be so important and valuable, in fact, some would be kept in the home or at least in holding pens very close to the...]]></description>
<dc:creator><![CDATA[Schwab, I. R.]]></dc:creator>
<dc:date>2012-05-15T13:21:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301646</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301646</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Paediatrics, Public health, Conjunctiva, Cornea, Eye (globe), Ocular surface, Neurology, Epidemiology]]></dc:subject>
<dc:title><![CDATA[The changing spectrum of microbial keratitis: is microsporia increasing as a cause of microbial keratitis or is it a previously unrecognised cause?]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Editorials</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>774</prism:startingPage>
<prism:endingPage>775</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/776?rss=1">
<title><![CDATA[Review of endophthalmitis following Boston keratoprosthesis type 1]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/776?rss=1</link>
<description><![CDATA[
<p>Endophthalmitis remains one of the most damaging and challenging complications following Boston keratoprosthesis type 1 (KPro) surgery. The authors reviewed the literature from 2001 onward to identify cases of endophthalmitis following KPro surgery and present an additional case of endophthalmitis in a patient with Stevens Johnson syndrome. The prevalence of endophthalmitis between 2001 and 2011 was 5.4%. Gram-positive bacteria are the most common agents responsible for endophthalmitis in this patient population while gram-negative bacteria and fungi are emerging pathogens. Risk factors for endophthalmitis include preoperative diagnosis of cicatricial disease and postoperative infectious keratitis, glaucoma drainage device erosion and non-compliance with antibiotic prophylaxis. Additional studies on the prevention and treatment of endophthalmitis are required to improve the overall prognosis of these patients.</p>
]]></description>
<dc:creator><![CDATA[Robert, M.-C., Moussally, K., Harissi-Dagher, M.]]></dc:creator>
<dc:date>2012-05-15T13:21:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301263</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301263</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Angle, Choroid, Cornea, Eye (globe), Intraocular pressure, Ocular surface, Glaucoma]]></dc:subject>
<dc:title><![CDATA[Review of endophthalmitis following Boston keratoprosthesis type 1]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Review</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>776</prism:startingPage>
<prism:endingPage>780</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/781?rss=1">
<title><![CDATA[The great and the wrong: Dr William Briggs]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/781?rss=1</link>
<description><![CDATA[ <p>Dr William Briggs (<cross-ref type="fig" refid="fig1">figure 1</cross-ref>) was a 17th century physician with the distinction of being one of the first to specialise in ophthalmology. Despite competition with established quacks and charlatans such as the illiterates Sir William Read and Roger Grant, he established a reputation as an honest ophthalmic physician and made some significant contributions to the subject.</p> <p>He was born in Norwich in 1650. At the age of 13 he was admitted to Corpus Christi College, Cambridge, where he obtained his BA, MA and his MD in 1677. He was made a Fellow of the College, a position he held from 1668 to 1682. He pursued further study at Montpellier under Raymond Vieussens, an expert in the anatomy of the brain, which influenced him to pursue his special interest in the anatomy of the visual system on his return to Cambridge, England.</p> <p>The landmark feature of his...]]></description>
<dc:creator><![CDATA[Keeler, R., Dua, A., Singh, A. D., Dua, H. S.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301953</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301953</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Vision, Neurology]]></dc:subject>
<dc:title><![CDATA[The great and the wrong: Dr William Briggs]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Cover illustration</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>781</prism:startingPage>
<prism:endingPage>782</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/783?rss=1">
<title><![CDATA[The number of ophthalmologists in practice and training worldwide: a growing gap despite more than 200 000 practitioners]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/783?rss=1</link>
<description><![CDATA[
<sec><st>Background/aims</st>
<p>To assess the current number of ophthalmologists practicing worldwide in 2010 and to create a system for maintaining, collecting and improving the accuracy of data on ophthalmologists per population, ophthalmologists performing surgery, growth rate of the profession, and the number of residents in training.</p>
</sec>
<sec><st>Methods</st>
<p>Between March 2010 and April 2010, the International Council of Ophthalmology emailed a standardised survey of 12 questions to 213 global ophthalmic societies. Missing data and additional information were gathered from direct correspondences with ophthalmologist contacts.</p>
</sec>
<sec><st>Results</st>
<p>The total number of ophthalmologists reported was 204 909. Data are presented for 193 countries. Information was obtained from 67 countries on the number of ophthalmologists doing surgery, entering practice, leaving practice, rate of growth and resident training.</p>
</sec>
<sec><st>Conclusion</st>
<p>The survey results show that despite over 200 000 ophthalmologists worldwide, there is currently a significant shortfall of ophthalmologists in developing countries. Furthermore, although the number of practitioners is increasing in developed countries, the population aged 60+ is growing at twice the rate of the profession. To meet this widening gap between need and supply, it is necessary to aggressively train eye care teams now to alleviate the current and anticipated deficit of ophthalmologists worldwide.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Resnikoff, S., Felch, W., Gauthier, T.-M., Spivey, B.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301378</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301378</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Press releases]]></dc:subject>
<dc:title><![CDATA[The number of ophthalmologists in practice and training worldwide: a growing gap despite more than 200 000 practitioners]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Global issues</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>783</prism:startingPage>
<prism:endingPage>787</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/788?rss=1">
<title><![CDATA[First clinical results with a new 200 kHz femtosecond laser system]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/788?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>The aim of this study was to perform the first femtosecond laser cuts with a new prototype femtosecond laser, in vivo and to evaluate its safety, stability and efficacy.</p>
</sec>
<sec><st>Methods</st>
<p>A LASIK cut was performed with a prototype 200 kHz femtosecond laser in both eyes of nine patients and one eye of two patients (20 individual eyes in total). A complete ophthalmic examination was performed preoperatively and postoperatively at 1, 3, 6 and 12 months after the procedure.</p>
</sec>
<sec><st>Results</st>
<p>In the pilot series of 20 eyes, flap creation was possible in each case. The mean preoperative manifest refractive spherical equivalent was &Agrave;&ndash;4.22&nbsp;D (SD&plusmn;61.22&nbsp;D). The postoperative spherical equivalent refraction was &Agrave;&ndash;0.1&nbsp;D (SD&plusmn;60.26&nbsp;D) at 1&nbsp;month, &Agrave;&ndash;0.22&nbsp;D (SD&plusmn;60.24&nbsp;D) at 3&nbsp;months and &Agrave;&ndash;0.15&nbsp;D (SD&plusmn;60.16&nbsp;D) 12&nbsp;months after surgery.</p>
</sec>
<sec><st>Conclusions</st>
<p>Femto-LASIK with this new laser system showed high levels of safety, stability and efficacy without any enhancement.</p>
</sec>
<sec><st>Clinical trials registration</st>
<p><A HREF="http://www.dimdi.de">http://www.dimdi.de</A>. DE/CA126/AP4/3332/27/09. Bfam registration 09/03/2009, DE/CA126.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Winkler von Mohrenfels, C., Khoramnia, R., Salgado, J., Wullner, C., Donitzky, C., Maier, M., Lohmann, C. P.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300073</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300073</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Ophthalmologic surgical procedures]]></dc:subject>
<dc:title><![CDATA[First clinical results with a new 200 kHz femtosecond laser system]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Innovations</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>788</prism:startingPage>
<prism:endingPage>792</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/793?rss=1">
<title><![CDATA[Diagnosis, clinical features and treatment outcome of microsporidial keratoconjunctivitis]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/793?rss=1</link>
<description><![CDATA[
<sec><st>Aim</st>
<p>To report the clinical and microbiological profile of patients with microsporidial keratoconjunctivitis in a tertiary eye care centre in India.</p>
</sec>
<sec><st>Methods</st>
<p>A retrospective analysis of medical records of all cases of microbiologically confirmed microsporidial keratoconjunctivitis, who presented between March 2007 and October 2010, was done. In a single-centre, institutional setting, 278 eyes of 277 apparently healthy patients were analysed.</p>
</sec>
<sec><st>Results</st>
<p>The mean age was 36&plusmn;14&nbsp;years (range 6&ndash;80). The mean duration of symptoms was 7.7&plusmn;6.2&nbsp;days (range 1&ndash;60). Keratic precipitates were present in 20.1% patients. A superficial scar was present in 39.2% patients. Majority (26.6%) of the patients reported in the month of August. Microscopic examination of corneal scraping, using potassium hydroxide with calcofluor white and Gram stain, demonstrated microsporidial spores in 98.9% and 89.7% cases, respectively. Patients received either topical 0.02% polyhexamethylene biguanide or lubricants. The mean time for resolution was 6.0&plusmn;2.9&nbsp;days (range 2&ndash;18). Final visual acuity was &ge;20/30 in 75.1% cases.</p>
</sec>
<sec><st>Conclusions</st>
<p>Microsporidial keratoconjunctivitis is common in India. It is seasonal, can occur in healthy individuals and can be diagnosed using simple microbiological methods. Treatment outcome is generally satisfactory.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Das, S., Sharma, S., Sahu, S. K., Nayak, S. S., Kar, S.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301227</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301227</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Conjunctiva, Cornea, Ocular surface]]></dc:subject>
<dc:title><![CDATA[Diagnosis, clinical features and treatment outcome of microsporidial keratoconjunctivitis]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>793</prism:startingPage>
<prism:endingPage>795</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/796?rss=1">
<title><![CDATA[Mooren's ulcer in children]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/796?rss=1</link>
<description><![CDATA[
<sec><st>Purpose</st>
<p>To describe the epidemiology, clinical features, management and outcomes of paediatric Mooren's peripheral ulcerative keratitis.</p>
</sec>
<sec><st>Methods</st>
<p>All patients with Mooren's ulcer aged &lt;18&nbsp;years presenting at a single centre from 1987 to 2010 were enrolled. Epidemiological features, symptomatology, clinical signs, disease severity, investigations, treatment, outcomes and complications were studied. Main outcome measures were anatomical and functional outcomes, disease activity and complications.</p>
</sec>
<sec><st>Results</st>
<p>14 eyes of 11 children (seven males and four females with an average age of 12.45&plusmn;2.25&nbsp;years at presentation) with Mooren's ulcer were included. Eight cases were unilateral and three bilateral. Symptoms at presentation were more severe than in adults. Trauma was the commonest predisposing factor. Eight eyes had severe corneal involvement. Medical management included intensive topical steroid therapy, oral steroid therapy and immunosuppressant agents. Surgical therapy included tissue adhesive and bandage contact lens application, amniotic membrane transplantation, optical penetrating keratoplasty and limbal stem cell transplantation and was performed in most eyes as part of primary management or later during the disease course. Patients were followed up for a mean of 69.1&nbsp;weeks. Ten eyes healed successfully and one developed descemetocele. Three eyes developed secondary infections, one of which ultimately became phthisical. In most eyes, final vision either remained stable or was better than at presentation.</p>
</sec>
<sec><st>Conclusions</st>
<p>Our data suggest demographic and clinical features of Mooren's ulcer in children differ from those in adults. Good anatomical results and stable visual results can be achieved with appropriate medical and surgical therapies. Systemic steroids and immunosuppression should be used judiciously with close monitoring.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Mathur, A., Ashar, J., Sangwan, V.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300985</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300985</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Paediatrics, Ophthalmologic surgical procedures, Cornea, Ocular surface, Epidemiology]]></dc:subject>
<dc:title><![CDATA[Mooren's ulcer in children]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>796</prism:startingPage>
<prism:endingPage>800</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/801?rss=1">
<title><![CDATA[Reliability and validity of conjunctival ultraviolet autofluorescence measurement]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/801?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Conjunctival ultraviolet autofluorescence (UVAF) photography was developed to detect and characterise pre-clinical sunlight-induced UV damage. The reliability of this measurement and its relationship to outdoor activity are currently unknown.</p>
</sec>
<sec><st>Methods</st>
<p>599 people aged 16&ndash;85&nbsp;years in the cross-sectional Norfolk Island Eye Study were included in the validation study. 196 UVAF individual photographs (49 people) and 60 UVAF photographs (15 people) of Norfolk Island Eye Study participants were used for intra- and inter-observer reliability assessment, respectively. Conjunctival UVAF was measured using UV photography. UVAF area was calculated using computerised methods by one grader on two occasions (intra-observer analysis) or two graders (inter-observer analysis). Outdoor activity category, during summer and winter separately, was determined with a UV questionnaire. Total UVAF equalled the area measured in four conjunctival areas (nasal/temporal conjunctiva of right and left eyes).</p>
</sec>
<sec><st>Results</st>
<p>Intra-observer (_c=0.988, 95% CI 0.967 to 0.996, p&lt;0.001), and inter-observer concordance correlation coefficients (_c=0.924, 95% CI 0.870 to 0.956, p&lt;0.001) of total UVAF exceeded 0.900. When grouped according to 10&nbsp;mm<sup>2</sup> total UVAF increments, intra- and inter-observer reliability was very good (=0.81) and good (=0.71), respectively. Increasing time outdoors was strongly with increasing total UVAF in summer and winter (p<SUB>trend</SUB> &lt;0.001).</p>
</sec>
<sec><st>Conclusion</st>
<p>Intra- and inter-observer reliability of conjunctival UVAF is high. In this population, UVAF correlates strongly with the authors' survey-based assessment of time spent outdoors.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Sherwin, J. C., McKnight, C. M., Hewitt, A. W., Griffiths, L. R., Coroneo, M. T., Mackey, D. A.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301255</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301255</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Reliability and validity of conjunctival ultraviolet autofluorescence measurement]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>801</prism:startingPage>
<prism:endingPage>805</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/806?rss=1">
<title><![CDATA[Corneal biomechanical properties and intraocular pressure measurement in patients with nanophthalmos]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/806?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>To compare the biomechanical properties of the cornea and intraocular pressure (IOP) between patients with nanophthalmos and age-matched controls.</p>
</sec>
<sec><st>Methods</st>
<p>In this prospective, cross-sectional and comparative study, 27 eyes of 27 healthy individuals (control group) and 27 eyes of 27 patients with nanophthalmos (study group) were enrolled. Corneal hysteresis (CH), corneal resistance factor (CRF), corneal compensated intraocular pressure (IOPcc) and Goldmann correlated intraocular pressure (IOPg) were recorded for the right eye of each participant using Reichert Ocular Response Analyser measurements. Also, all participants in this study underwent a standardised ocular examination including IOP measurement with Goldmann applanation tonometry (IOP<SUB>GAT</SUB>), central corneal thickness and axial length (AL) assessments.</p>
</sec>
<sec><st>Results</st>
<p>Mean CH in the nanophthalmic eyes and in the control eyes were 13.3&plusmn;2.4&nbsp;mm&nbsp;Hg and 11.6&plusmn;1.7&nbsp;mm&nbsp;Hg, respectively (p=0.003); mean CRF values in the nanophthalmic and the control eyes were 13.2&plusmn;1.8&nbsp;mm&nbsp;Hg and 11.4&plusmn;1.9&nbsp;mm&nbsp;Hg, respectively (p=0.001). Mean IOP<SUB>GAT</SUB> was 15.2&plusmn;3.3&nbsp;mm&nbsp;Hg in the nanophthalmic eyes and 13.4&plusmn;2.7&nbsp;mm&nbsp;Hg in the control group (p=0.031); mean IOPg values for the nanophthalmic and the control groups were 17.1&plusmn;5.3&nbsp;mm&nbsp;Hg and 14.7&plusmn;3.5&nbsp;mm&nbsp;Hg, respectively (p=0.042). Mean IOPcc values in the nanophthalmic and the control group were 13.6&plusmn;6.1&nbsp;mm&nbsp;Hg and 14.8&plusmn;3.2&nbsp;mm&nbsp;Hg, respectively (p=0.365).</p>
</sec>
<sec><st>Conclusion</st>
<p>The CH, CRF, IOPg and IOP<SUB>GAT</SUB> were significantly higher in the nanophthalmic eyes, whereas no significant differences in IOPcc were observed. These findings may be taken into account when measuring IOP values in patients with nanophthalmos.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Altan, C., Kara, N., Baz, O., Satana, B., Demirok, A., Yilmaz, O. F.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300557</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300557</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Corneal biomechanical properties and intraocular pressure measurement in patients with nanophthalmos]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>806</prism:startingPage>
<prism:endingPage>810</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/811?rss=1">
<title><![CDATA[Frequency and associated factors of structural progression of open-angle glaucoma in the Beijing Eye Study]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/811?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>To examine factors associated with progression of open-angle glaucoma in a population-based setting.</p>
</sec>
<sec><st>Methods</st>
<p>The population-based Beijing Eye Study, which included 4439 subjects with an age of 40+&nbsp;years in the year 2001, was repeated in 2006. Optic disc photographs of the baseline examination versus follow-up examination were compared.</p>
</sec>
<sec><st>Results</st>
<p>Out of 111 open-angle glaucoma patients examined in 2001, 77 (69%) subjects participated in the follow-up examination and 16 (21%) eyes showed glaucoma progression. Glaucoma progression was associated with smaller rim area (p=0.001), larger &beta; zone (p=0.037), higher frequency of &beta; zone increase during follow-up (p=0.01), higher prevalence of disc haemorrhages (p=0.01) and higher single intraocular pressure (p=0.04). In multiple regression analysis, only smaller rim area remained significantly associated with glaucoma progression. Glaucoma progression was not associated with optic disc size (p=0.70), mean blood pressure (p=0.43), ocular perfusion pressure (p=0.96), retinal vessel diameter and retinal microvascular abnormalities (all p&gt;0.10), prevalence of diabetes mellitus (p=0.75) and arterial hypertension (p=0.26), prevalence of dyslipidaemia (p=0.28), refractive error (p=0.69), and central corneal thickness (p=0.97).</p>
</sec>
<sec><st>Conclusions</st>
<p>In a population-based setting in adult Chinese, factors showing an association with open-angle glaucoma progression were an advanced stage of the disease (ie, small rim), presence of disc haemorrhages, larger area of &beta; zone and higher frequency of &beta; zone increase, and higher intraocular pressure. Glaucoma progression was not significantly associated with optic disc size, central corneal thickness, retinal vessel diameter and retinal microvascular abnormalities, and systemic diseases such as diabetes mellitus and arterial hypertension.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Wang, Y. X., Hu, L. N., Yang, H., Jonas, J. B., Xu, L.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301224</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301224</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Angle, Intraocular pressure, Optic nerve, Glaucoma, Optics and refraction]]></dc:subject>
<dc:title><![CDATA[Frequency and associated factors of structural progression of open-angle glaucoma in the Beijing Eye Study]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>811</prism:startingPage>
<prism:endingPage>815</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/816?rss=1">
<title><![CDATA[Avoidable sight loss from glaucoma: is it unavoidable?]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/816?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>To review the characteristics of patients attending a tertiary ophthalmic referral centre certified as sight impaired (SI) or severely sight impaired (SSI) from glaucoma.</p>
</sec>
<sec><st>Methods</st>
<p>One hundred consecutive patients certified SI/SSI from the Glaucoma Service at Moorfields Eye Hospital, London, from January 2007 were identified from the England and Wales certification of visual impairment database. Clinical and demographic data were collected from hospital case records.</p>
</sec>
<sec><st>Results</st>
<p>The median (IQR) age of patients at presentation was 66.3 (55.6 to 75.3) years; median (IQR) interval to certification was 62.2 (22.5 to 129.3) months. Fifty-seven patients presented with bilateral SSI (median (IQR) age 70.4 (59.0 to 76.9) years); interval to certification was 35.4 (5.6 to 78.1) months. Seventeen patients presented with a bilateral SI (median (IQR) age 62.1 (58.7 to 68.4) years; median (IQR) interval to certification: 137.4 (64.4 to 190.4) months). Twenty-eight patients showed disease progression while under National Health Service hospital eye service care, five of whom had no certifiable visual impairment in either eye at presentation. This was attributed to inadequate intraocular pressure control; five of these patients (18%) were deemed poorly compliant to topical hypotensive medication.</p>
</sec>
<sec><st>Conclusions</st>
<p>Over 80% patients on the certification of visual impairment register from Moorfields Eye Hospital with glaucoma as the primary cause had a significant visual disability at presentation, with almost two-thirds of patients presenting bilaterally &lsquo;blind&rsquo;. There appear to be delays to certification. Despite being under the hospital eye service, a number of glaucoma patients still progress to certifiable visual impairment.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Kotecha, A., Fernandes, S., Bunce, C., Franks, W. A.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301499</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301499</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Angle, Intraocular pressure, Glaucoma]]></dc:subject>
<dc:title><![CDATA[Avoidable sight loss from glaucoma: is it unavoidable?]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>816</prism:startingPage>
<prism:endingPage>820</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/821?rss=1">
<title><![CDATA[Risk factors for anxiety and depression in patients with glaucoma]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/821?rss=1</link>
<description><![CDATA[
<sec><st>Aim</st>
<p>To assess the risk factors for anxiety and depression in patients with glaucoma.</p>
</sec>
<sec><st>Methods</st>
<p>Anxiety and depression in 408 patients with glaucoma were evaluated using the hospital anxiety and depression scale (HADS) questionnaire, which consists of two subscales, representing HADS-anxiety (HADS-A) and HADS-depression (HADS-D). To identify the risk factors for anxiety and depression, the stepwise and multiple linear regression analyses were carried out with the HADS-A and HADS-D subscores as dependent variables and demographic and clinical features as independent variables.</p>
</sec>
<sec><st>Results</st>
<p>A stepwise linear regression analysis revealed the significantly related factors to be age for HADS-A (&beta;=&ndash;0.046, p=0.0007) and HADS-D (&beta;=0.035, p=0.011) and the mean deviation of the Humphrey Visual Field Analyzer 30-2 (HFA30-2) in the better eye for HADS-D (&beta;=&ndash;0.095, p=0.0026). Based on multiple linear regression analyses, significant relationships were confirmed between age and the HADS-A subscore (&beta;=&ndash;0.046, p=0.0008). Significant relationships were also confirmed between age (&beta;=0.037, p=0.0077) or the mean deviation of HFA30-2 in the better eye (&beta;=&ndash;0.094, p=0.0036) and the HADS-D subscore.</p>
</sec>
<sec><st>Conclusion</st>
<p>A younger age was thus found to be a risk factor for anxiety, while an older age and increasing glaucoma severity were risk factors for depression in patients with glaucoma.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Mabuchi, F., Yoshimura, K., Kashiwagi, K., Yamagata, Z., Kanba, S., Iijima, H., Tsukahara, S.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300910</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300910</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Angle, Intraocular pressure, Glaucoma]]></dc:subject>
<dc:title><![CDATA[Risk factors for anxiety and depression in patients with glaucoma]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>821</prism:startingPage>
<prism:endingPage>825</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/826?rss=1">
<title><![CDATA[Spanish multicenter tafluprost tolerability study]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/826?rss=1</link>
<description><![CDATA[
<sec><st>Aim</st>
<p>To evaluate the ocular surface symptoms and signs associated with preservative-free 0.0015% tafluprost in patients with glaucoma or ocular hypertension (OHT).</p>
</sec>
<sec><st>Methods</st>
<p>Prospective non-interventional, multicentre, observational study on 134 patients, naive or on previous treatment with another prostaglandin analogue. In each visit (V1 baseline visit, V2 at 1&nbsp;month and V3 at 3&nbsp;months), patients evaluated five ocular surface symptoms as: absent, mild, moderate and severe. Parallelly, the ophthalmologist assessed the tear break-up time, keratitis, conjunctival hyperaemia, blepharitis, Schirmer test and tear meniscus.</p>
</sec>
<sec><st>Results</st>
<p>Patients with OHT (n=71, 53%) experienced a statistically significant improvement of all symptoms: stinging/burning/irritation, itching, foreign body sensation, tearing and dryness sensation at V3, while glaucoma patients improved all symptoms at both V2 and V3. In patients with OHT, all signs except Schirmer test improved and the decrease in hyperaemia was statistically significant. Eyes with glaucoma ameliorated the keratitis, hyperaemia and tear meniscus at V2 and V3 and the break-up time and blepharitis at V3. In the subset of patients with previous treatment (n=79, 58.9%), patients with OHT presented significant improvement of hyperaemia, yet the rest of signs did not decrease significantly or remained unchanged, while in patients with glaucoma all signs improved significantly at both visits. The intraocular pressure (IOP) drop in naive eyes was 22.2% (24.7&ndash;19.7&nbsp;mm&nbsp;Hg) in OHT and 29.5% (33.7&ndash;25.3&nbsp;mm&nbsp;Hg) in glaucoma eyes. In previously treated eyes, no statistically significant change in IOP was found.</p>
</sec>
<sec><st>Conclusion</st>
<p>Preservative-free tafluprost is a well tolerated hypotensive agent that can be used in eyes with surface problems and in naive eyes.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Milla, E., Stirbu, O., Rey, A., Duch, S., Buchacra, O., Robles, A., Navarro, C., Gil, R., Cordero, J. M.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301015</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301015</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Angle, Cornea, Eye Lids, Intraocular pressure, Ocular surface, Glaucoma]]></dc:subject>
<dc:title><![CDATA[Spanish multicenter tafluprost tolerability study]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>826</prism:startingPage>
<prism:endingPage>831</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/832?rss=1">
<title><![CDATA[Agreement among three types of spectral-domain optical coherent tomography instruments in measuring parapapillary retinal nerve fibre layer thickness]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/832?rss=1</link>
<description><![CDATA[
<sec><st>Backgrounds/aims</st>
<p>To evaluate the agreement of parapapillary retinal nerve fibre layer (RNFL) thickness among three spectral-domain optical coherence tomography (OCT) instruments.</p>
</sec>
<sec><st>Methods</st>
<p>Two hundred and three glaucomatous eyes and 88 normal eyes were imaged by Cirrus, RTVue and 3D OCT. The average and the four quadrant RNFL thicknesses were evaluated. Agreement among RNFL measurements was evaluated using Bland&ndash;Altman analysis and linear regression analysis. The percentage of each quadrant in the average RNFL thickness value was compared among the three instruments.</p>
</sec>
<sec><st>Results</st>
<p>Cirrus showed significantly smaller thickness values than RTVue (difference=8.8&nbsp;&mu;m, p&lt;0.0001) and 3D OCT (difference=8.1&nbsp;&mu;m, p&lt;0.0001). Although RNFL measurements among the instruments were highly correlated, the Bland&ndash;Altman analysis revealed proportional biases for most of the pair-wise agreements. Additionally, 3D OCT showed strong proportional biases with RTVue and 3D OCT. RTVue had a smaller occupied proportion of nasal quadrants (30.2%) and a larger proportion of inferior quadrants (32.4%) compared with Cirrus and 3D OCT.</p>
</sec>
<sec><st>Conclusions</st>
<p>RNFL measurements among the instruments were well correlated but had different values for thickness. The measurement circle of RTVue might be more superior-temporally located compared with the other instruments. Differences in the measurement protocols might be affected by the disagreements. These instruments should not be used interchangeably.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Kanamori, A., Nakamura, M., Tomioka, M., Kawaka, Y., Yamada, Y., Negi, A.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301084</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301084</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Angle, Intraocular pressure, Glaucoma]]></dc:subject>
<dc:title><![CDATA[Agreement among three types of spectral-domain optical coherent tomography instruments in measuring parapapillary retinal nerve fibre layer thickness]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>832</prism:startingPage>
<prism:endingPage>837</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/838?rss=1">
<title><![CDATA[The effect on quality of life of long-term botulinum toxin A injections to maintain ocular alignment in adult patients with strabismus]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/838?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>There is considerable evidence to show that strabismus patients report their quality of life (QoL) as lower than normal controls. While the majority of patients with strabismus are treated with surgery there are a number of cases where surgery is not possible and good long-term ocular alignment can be maintained with repeated injections of botulinum toxin.</p>
</sec>
<sec><st>Methods</st>
<p>65 patients who had undergone over 25 injections of botulinum toxin A for long-term control of their deviation were identified and asked to fill in and return the Adult Strabismus questionnaire (AS-20) to assess their QoL.</p>
</sec>
<sec><st>Results</st>
<p>46 questionnaires were available for analysis. The mean AS-20 score in our patients compared favourably with that reported for normal controls and was much higher than that reported for patients with strabismus.</p>
</sec>
<sec><st>Conclusion</st>
<p>Long-term injections with botulinum toxin A is a good treatment for maintaining ocular alignment if squint surgery is not indicated and those patients receiving treatment score near the level of normal controls in QoL terms.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Hancox, J., Sharma, S., MacKenzie, K., Adams, G.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301332</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301332</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Muscles, Neurology]]></dc:subject>
<dc:title><![CDATA[The effect on quality of life of long-term botulinum toxin A injections to maintain ocular alignment in adult patients with strabismus]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>838</prism:startingPage>
<prism:endingPage>840</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/841?rss=1">
<title><![CDATA[Primary bilateral silicone frontalis suspension for good levator function ptosis in oculopharyngeal muscular dystrophy]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/841?rss=1</link>
<description><![CDATA[
<sec><st>Aim</st>
<p>To evaluate outcomes of patients with oculopharyngeal muscular dystrophy (OPMD) with levator function (LF) &ge;10mm who underwent primary bilateral silicone frontalis suspension.</p>
</sec>
<sec><st>Methods</st>
<p>31 patients with OPMD satisfied the following inclusion criteria: LF &ge;10&nbsp;mm; no previous eyelid surgery; and pre-operative measurements, silcone frontalis suspension and post-operative measurements performed by a single individual. The following data were collected: age; gender; pre-operative margin reflex distance (MRD), palpebral fissure height (PF), and LF; post-operative MRD, PF and lagophthalmos; follow-up; and complications.</p>
</sec>
<sec><st>Results</st>
<p>Mean age at surgery was 61.5&plusmn;5.8&nbsp;years. Pre-operative measurements for MRD, PF and LF were &ndash;0.05&plusmn;0.82&nbsp;mm (OD), &ndash;0.13&plusmn;0.91&nbsp;mm (OS); 5.2&plusmn;1.2&nbsp;mm (OD), 5.2&plusmn;1.3&nbsp;mm (OS); 11.6&plusmn;1.3&nbsp;mm (OD), and 11.7&plusmn;1.3&nbsp;mm (OS), respectively. Post-operative measurements for MRD and PF were 2.23&plusmn;0.97&nbsp;mm (OD), 2.10&plusmn;1.09&nbsp;mm (OS), 7.9&plusmn;1.4&nbsp;mm (OD), and 7.7&plusmn;1.6&nbsp;mm (OS), respectively (all p&lt;0.0001). The mean follow-up period was 22.8&plusmn;22.4&nbsp;months. There was no sling (infection or extrusion) or ophthalmic (significant corneal compromise) complication after the surgery. Six patients (19%) underwent early (within 3&nbsp;months) tightening of their slings for under correction. Three patients (10%) underwent late (&gt;39&nbsp;months) tightening of their frontalis slings for recurrent ptosis after their initial surgery.</p>
</sec>
<sec><st>Conclusions</st>
<p>Primary bilateral silicone frontalis suspension for good LF ptosis secondary to OPMD appears to be an effective, safe treatment which gives symmetrical upper lid elevation. Early sling adjustment may be required to attain optimal eyelid height and late tightening for expectant loosening of the sling is safe and effective.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Allen, R. C., Zimmerman, M. B., Watterberg, E. A., Morrison, L. A., Carter, K. D.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300667</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300667</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Neurology]]></dc:subject>
<dc:title><![CDATA[Primary bilateral silicone frontalis suspension for good levator function ptosis in oculopharyngeal muscular dystrophy]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>841</prism:startingPage>
<prism:endingPage>845</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/846?rss=1">
<title><![CDATA[The impact of bilateral or unilateral cataract surgery on visual functioning: when does second eye cataract surgery benefit patients?]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/846?rss=1</link>
<description><![CDATA[
<sec><st>Aim</st>
<p>To examine the impact of bilateral or unilateral cataract surgery on visual functioning.</p>
</sec>
<sec><st>Methods</st>
<p>The Singapore Malay Eye Study is a population-based study of 3280 Singapore Malay patients aged 40&ndash;80&nbsp;years, of which 3225 had data available for inclusion. Cataracts were graded from digital lens photographs according to the Wisconsin scale. Study subjects were categorised as having: bilateral cataract surgery performed; unilateral cataract surgery performed with minimal cataract in the fellow eye; unilateral cataract surgery performed with significant cataract in the fellow eye; and bilateral cataract. Visual functioning was assessed using the modified VF-9 scale culturally adapted for Singaporean individuals, validated by Rasch analysis. The overall Rasch-modified vision-specific functioning score was compared across the four groups after adjusting for confounders such as age, gender, ocular and systemic comorbidities.</p>
</sec>
<sec><st>Results</st>
<p>Persons with bilateral cataract had poorer visual functioning than those who had bilateral cataract surgery (mean visual functioning scores 3.38 vs 3.11, respectively, p=0.029). When compared with bilateral surgery, visual functioning improvements among patients with unilateral cataract surgery depended on the status of the fellow eye, with improvements only seen if the fellow eye had significant cataract (mean visual functioning scores 2.81 vs 3.25, p=0.019) or poor visual acuity (mean visual functioning scores 2.78 vs 3.25, p=0.018) after adjusting for confounders.</p>
</sec>
<sec><st>Conclusions</st>
<p>Bilateral cataract surgery was associated with greater visual functioning over unilateral cataract surgery when the fellow eye had a significant cataract or poor presenting visual acuity, supporting the current practice of second eye surgery depending on the fellow eye's cataract status and visual acuity.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Tan, A. C. S., Tay, W. T., Zheng, Y. F., Tan, A. G., Wang, J. J., Mitchell, P., Wong, T. Y., Lamoureux, E. L.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301233</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301233</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Lens and zonules, Editor's choice, Epidemiology]]></dc:subject>
<dc:title><![CDATA[The impact of bilateral or unilateral cataract surgery on visual functioning: when does second eye cataract surgery benefit patients?]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>846</prism:startingPage>
<prism:endingPage>851</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/852?rss=1">
<title><![CDATA[The clinical course of juvenile idiopathic arthritis-associated uveitis in childhood and puberty]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/852?rss=1</link>
<description><![CDATA[
<sec><st>Aim</st>
<p>The long-term course of juvenile idiopathic arthritis (JIA)-associated uveitis is not known yet. This study investigates the course and activity of JIA-associated uveitis in childhood and puberty.</p>
</sec>
<sec><st>Design</st>
<p>Retrospective study of the clinical data of 62 JIA patients with uveitis. The main outcome measurements consisted of uveitis activity measured as mean cell grade in the anterior chamber, topical and systemic medication and ocular complications related to disease activity. All data were scored and evaluated per year of age.</p>
</sec>
<sec><st>Results</st>
<p>Uveitis activity took a biphasic course with a quiet phase around the age of 9&nbsp;years and showed increased activity during early teenage years. The biphasic course was significantly related to age (p=0.048) but not to uveitis duration. More patients were treated with systemic immunosuppressive medication in estimated puberty years (63% in boys, 53% in girls) compared with prepuberty years (46% and 28%, respectively), although the difference was only significant in girls (p&lt;0.001). The presence of cystoid macular oedema and papillitis was not significantly related to estimated puberty, but the development of an hypotonous eye was more frequently observed in boys in estimated puberty years (p=0.026).</p>
</sec>
<sec><st>Conclusions</st>
<p>JIA-associated uveitis appears to take a biphasic course with the second phase of activity during early teenage years and more treatment with systemic immunosuppressive medication occurred during estimated puberty compared with prepuberty years.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Hoeve, M., Kalinina Ayuso, V., Schalij-Delfos, N. E., Los, L. I., Rothova, A., de Boer, J. H.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301023</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301023</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Retina]]></dc:subject>
<dc:title><![CDATA[The clinical course of juvenile idiopathic arthritis-associated uveitis in childhood and puberty]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>852</prism:startingPage>
<prism:endingPage>856</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/857?rss=1">
<title><![CDATA[Increased risk of uveitis in coeliac disease: a nationwide cohort study]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/857?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Case reports suggest a potential association between coeliac disease (CD) and uveitis, but larger well-controlled studies are lacking. The aim of this study was therefore to examine the risk of uveitis in patients with biopsy-verified CD.</p>
</sec>
<sec><st>Methods</st>
<p>Small intestinal biopsy reports performed between July 1969 and February 2008 were collected from all (n=28) pathology departments in Sweden. From these reports, 29 044 patients with CD (equals villous atrophy, Marsh 3) were identified. Uveitis was defined according to relevant International Classification of Disease codes in the Swedish National Patient Register. Cox regression was used to estimate HR for uveitis in individuals with CD compared with those in reference individuals matched for age, sex, county and calendar year.</p>
</sec>
<sec><st>Results</st>
<p>During follow-up, 148 patients with CD developed uveitis (expected count 112), corresponding to a HR of 1.32 (95% CI 1.10 to 1.58). The absolute risk of uveitis was 50/100 000 person-years in CD. The risk estimate did not change more than marginally when adjusted for type 1 diabetes, rheumatoid arthritis and autoimmune thyroid disease (HR 1.30; 95% CI 1.08 to 1.56). The risk of uveitis remained significantly increased even 5&nbsp;years after CD diagnosis (HR 1.31; 95% CI 1.04 to 1.64).</p>
</sec>
<sec><st>Conclusion</st>
<p>A moderately increased risk of uveitis was found in patients with biopsy-verified CD. CD might be considered in patients with uveitis of unknown aetiology.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Mollazadegan, K., Kugelberg, M., Tallstedt, L., Ludvigsson, J. F.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301051</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301051</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiology]]></dc:subject>
<dc:title><![CDATA[Increased risk of uveitis in coeliac disease: a nationwide cohort study]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>857</prism:startingPage>
<prism:endingPage>861</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/862?rss=1">
<title><![CDATA[Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/862?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>To describe and compare the causative organisms, clinical features and visual outcomes of endophthalmitis following intravitreal injection (IVI) to endophthalmitis following cataract surgery.</p>
</sec>
<sec><st>Methods</st>
<p><unl>Patient population and setting:</unl> A retrospective case series of patients with acute endophthalmitis following either cataract surgery or IVI presenting to a tertiary referral centre&mdash;Sydney Eye Hospital&mdash;between 2007 and 2010. <unl>Main outcome measures</unl>: (1) identification of the causative organism; (2) time to presentation; (3) odds of improvement in visual acuity (VA) following treatment; (4) odds of final VA of counting fingers (CF) or less and (5) odds of enucleation.</p>
</sec>
<sec><st>Results</st>
<p>Of the 101 patients in our study, 48 had preceding cataract surgery and 53 had preceding IVI. There was an increased incidence of <I>Streptococcus</I> spp. endophthalmitis in post-IVI cases (24.53% vs 6.25%; OR 5.85; p=0.022). Endophthalmitis following IVI had increased likelihood of a final VA of CF or less (OR=6.0; p&lt;0.01), decreased likelihood of any improvement in acuity following treatment (OR=0.13; p&lt;0.01) and an increased likelihood of presenting within a week of the procedure (OR=3.93; p&lt;0.01). Endophthalmitis caused by <I>Streptococcus</I> spp. was associated with increased likelihood of a final VA of CF or less (OR=10.2; p&lt;0.01), decreased likelihood of any improvement in acuity following treatment (OR=0.06; p&lt;0.01) and increased likelihood of enucleation (OR=17.11; p&lt;0.01).</p>
</sec>
<sec><st>Conclusions</st>
<p>Endophthalmitis following IVI is associated with an increased incidence of <I>Streptococcus</I> spp. infection, earlier presentation and poorer visual outcomes when compared with endophthalmitis following cataract surgery.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Simunovic, M. P., Rush, R. B., Hunyor, A. P., Chang, A. A.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301439</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301439</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Choroid, Eye (globe), Lens and zonules]]></dc:subject>
<dc:title><![CDATA[Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>862</prism:startingPage>
<prism:endingPage>866</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/867?rss=1">
<title><![CDATA[The role of the optical coherence tomography in identifying shape and size of idiopathic epiretinal membranes]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/867?rss=1</link>
<description><![CDATA[
<sec><st>AIM</st>
<p>Currently, the border of idiopathic epiretinal membranes (iERM) is outlined intraoperatively using vital dyes. Therefore, the authors set out to investigate the role of the preoperative retinal thickness map (RTM) of the optical coherence tomography (OCT) in identifying the shape and the size of the iERMs.</p>
</sec>
<sec><st>Methods</st>
<p>15 eyes of 15 patients with iERM who underwent vitrectomy with indocyanine green-assisted membrane peeling were included in this study. The authors analysed the intraoperative fundus images and preoperative Cirrus HD-OCT to detect the shape and the size of the iERM as well as the shape and the size of each thickness-indicating colour (white, red, orange and yellow) on the RTM, respectively. The correlation of areas and morphologic characteristics between both groups was explored.</p>
</sec>
<sec><st>Results</st>
<p>Analysis of iERM morphologic characteristics (shape) showed a similarity between the iERM contour and the corresponding RTM in 13 cases (86.6%). Furthermore, retinal folds were found in six iERMs and in their corresponding RTMs. Analysis of iERM size (area) revealed a positive correlation between the iERM area and each studied coloured area in RTM. The most significant correlation was between iERM and the red area (440&ndash;480&nbsp;&mu;m; r=0.87, p&lt;0.0001).</p>
</sec>
<sec><st>Conclusion</st>
<p>The iERM-related retinal folds are clearly distinguishable on the HD-OCT. The red area in RTM representing the 440&ndash;480&nbsp;&mu;m retinal thickness can be a reliable predictor of the extent and the shape of the iERM.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Hajnajeeb, B., Georgopoulos, M., Sayegh, R., Geitzenauer, W., Schmidt-Erfurth, U.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300629</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300629</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Ophthalmologic surgical procedures, Retina, Unlocked]]></dc:subject>
<dc:title><![CDATA[The role of the optical coherence tomography in identifying shape and size of idiopathic epiretinal membranes]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>867</prism:startingPage>
<prism:endingPage>871</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/872?rss=1">
<title><![CDATA[Risk of selected eye diseases in people admitted to hospital for hypertension or diabetes mellitus: record linkage studies]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/872?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>Associations among hypertension, diabetes mellitus and some ophthalmic diseases are well established; associations with others are more equivocal. The aim was to quantify associations accurately using large epidemiological datasets.</p>
</sec>
<sec><st>Methods</st>
<p>Analysis of the Oxford Record Linkage Study (ORLS), 1963&ndash;1998, and English linked hospital episode statistics (LHES), 1999&ndash;2010; calculation of rate ratios of eye disease in a hypertension cohort and a diabetes cohort, compared with a reference cohort as control.</p>
</sec>
<sec><st>Results</st>
<p>Risk of cataract following hypertension was marginally elevated (rate ratio ORLS 1.15, 95% CI 1.00 to 1.31; LHES 1.06, 1.01 to 1.10), as was risk of glaucoma (LHES 1.07, 1.00 to 1.14) and age-related macular degeneration (AMD) (LHES 1.14, 1.02 to 1.27). Risk of retinal vein or artery occlusion was elevated three- to fivefold in both populations. Risk of retinal detachment was elevated in LHES at 1.52 (1.43 to 1.73). Risk of cataract in diabetes was high in ORLS and LHES at, respectively, 2.95 (2.75 to 3.16) and 2.30 (2.24 to 2.35), as was risk of glaucoma: 2.47 (2.14 to 2.84) and 2.23 (2.15 to 2.30). Risks were high for AMD (10.3, 8.1 to 13.1, and 3.46, 3.35 to 3.58) and retinal detachment (3.41, 2.71 to 4.25, and 7.96, 7.63 to 8.30), and very high for retinal vein and artery occlusion.</p>
</sec>
<sec><st>Conclusions</st>
<p>With the exception of retinal vascular occlusion, elevations of risk of the ophthalmic diseases studied in hypertension were modest. By contrast, there were significant and substantial increases of risk for each eye disease in people with diabetes.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Goldacre, M. J., Wotton, C. J., Keenan, T. D. L.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301519</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301519</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Angle, Intraocular pressure, Lens and zonules, Retina, Glaucoma, Epidemiology]]></dc:subject>
<dc:title><![CDATA[Risk of selected eye diseases in people admitted to hospital for hypertension or diabetes mellitus: record linkage studies]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>872</prism:startingPage>
<prism:endingPage>876</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/877?rss=1">
<title><![CDATA[ERG monitoring of retinal function during systemic chemotherapy for retinoblastoma]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/877?rss=1</link>
<description><![CDATA[
<sec><st>Background/aims</st>
<p>We have previously introduced electroretinography (ERG) as a proxy for visual function to monitor for retinal toxicity due to intra-arterial chemotherapy for retinoblastoma in young children. In this paper, we report ERG results for patients with retinoblastoma receiving initial treatment with systemic chemotherapy.</p>
</sec>
<sec><st>Methods</st>
<p>Inclusion criteria were patients presenting with retinoblastoma at &lt;3&nbsp;months of age or &lt;6.0&nbsp;kg in weight, with large tumours not amenable to local laser treatment, cryotherapy or plaque brachytherapy. Patients received intravenous carboplatin 18.7&nbsp;mg/kg every 3&ndash;5&nbsp;weeks, contingent on recovery of blood counts, until they had grown sufficiently to receive intra-arterial chemotherapy. ERG was performed during examination under anaesthesia at monthly intervals, using contact lens electrodes and a hand-held ganzfeld stimulator. 30-Hertz flicker responses are reported.</p>
</sec>
<sec><st>Results</st>
<p>Four patients were treated for bilateral retinoblastoma. All eyes responded well to systemic chemotherapy. 30-Hertz flicker ERGs improved during treatment in all eyes, significantly in six of eight eyes, and at least in one eye of each patient.</p>
</sec>
<sec><st>Conclusion</st>
<p>Effective systemic chemotherapy for retinoblastoma in children who are too small for intra-arterial chemotherapy is compatible with significant increases in ERG amplitudes, even in eyes presenting with extinguished ERGs. ERG signals may increase independent of resolution of retinal detachment.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Brodie, S. E., Paulus, Y. M., Patel, M., Gobin, Y. P., Dunkel, I. J., Marr, B. P., Abramson, D. H.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301248</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301248</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Retina]]></dc:subject>
<dc:title><![CDATA[ERG monitoring of retinal function during systemic chemotherapy for retinoblastoma]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>877</prism:startingPage>
<prism:endingPage>880</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/881?rss=1">
<title><![CDATA[Periocular carboplatin for retinoblastoma: long-term report (12 years) on efficacy and toxicity]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/881?rss=1</link>
<description><![CDATA[
<sec><st>Aim</st>
<p>To report the experience of the authors with efficacy and toxicity of periocular chemotherapy over a 12-year period.</p>
</sec>
<sec><st>Methods</st>
<p>102 periocular injections of 2&nbsp;cc (10&nbsp;mg of carboplatin/1&nbsp;cc) were given every 4&ndash;6&nbsp;weeks in 33 eyes of 29 patients. Patient's data were reviewed retrospectively.</p>
</sec>
<sec><st>Results</st>
<p>Thirty-three eyes were followed for 7&ndash;148&nbsp;months following initiation of periocular injections, and 13 (39%) have avoided enucleation. There were two cases of second malignancy resulting in one death and one survivor, two survivors of metastatic disease, and two survivors of orbital recurrence. Twenty eyes were enucleated for disease progression at a mean time of 15&nbsp;months postinitiation of periocular carboplatin (POC). The Kaplan&ndash;Meier estimate of eye survival at 36&nbsp;months is 36%. Eleven of the 13 salvaged eyes received concurrent treatment with chemotherapy (n=4, 30%), external beam radiation and chemotherapy in (n=6, 46%), or brachytherapy (n=1, 8%). Two of the salvaged eyes (16%) were treated with POC alone. Orbital swelling occurred in 14/33 (42%) eyes. There were no symptomatic motility disorders. One severe toxicity reaction resulted in acute loss of vision, down to light perception, which failed to recover and one eye had progression of optic nerve pallor.</p>
</sec>
<sec><st>Conclusions</st>
<p>This paper demonstrates that POC has limited short-term and long-term systemic toxicity and most of the ocular complications were acute, not delayed. Only two select cases showed long-term complete responses to POC alone and the data do not support the use as monotherapy, although where it was used in combination with other modalities, 39% of the eyes were saved.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Marr, B. P., Dunkel, I. J., Linker, A., Abramson, D. H.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300517</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300517</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Periocular carboplatin for retinoblastoma: long-term report (12 years) on efficacy and toxicity]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>881</prism:startingPage>
<prism:endingPage>883</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/884?rss=1">
<title><![CDATA[Phenotypic variability of retinocytomas: preregression and postregression growth patterns]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/884?rss=1</link>
<description><![CDATA[
<sec><st>Aim</st>
<p>To describe the incidence of retinocytomas, their variability at presentation and their growth patterns both before and after regression.</p>
</sec>
<sec><st>Methods</st>
<p>Medical notes of the 525 patients of the Jules-Gonin Eye Hospital Retinoblastoma Clinic between 1964 and 2008 were reviewed and the charts of 36 patients with retinocytomas and/or phthisis bulbi were selected.</p>
</sec>
<sec><st>Results</st>
<p>The proportion of patients with retinocytomas and/or phthisis bulbi was 3.2%. The mean age at diagnosis was 28.7&plusmn;17&nbsp;years. Five tumours presented a cystic pattern (5.8%). Evidence of aggressive exophytic disease prior to spontaneous regression was documented in two eyes, and of invasive endophytic disease (regressed vitreous seeding or internal limiting membrane disruption) in three eyes. Twenty patients were followed with a mean follow-up of 44&plusmn;60&nbsp;months. Tumour growth was observed in 16% cases, benign cystic enlargement in 4% and malignant transformation in 12%.</p>
</sec>
<sec><st>Conclusion</st>
<p>This large study of retinocytomas substantially expands the published features of retinocytoma by describing the cystic nature of some retinocytomas as well as clinical characteristics of the endophytic and exophytic preregression growth patterns. The authors report two different patterns of reactivation: benign cystic enlargement and malignant transformation with or without cystic growth. Higher than previously reported frequency of growth and possible life-threatening complications impose close lifetime follow-up of retinocytoma patients.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Abouzeid, H., Balmer, A., Moulin, A. P., Mataftsi, A., Zografos, L., Munier, F. L.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300896</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300896</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Phenotypic variability of retinocytomas: preregression and postregression growth patterns]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>884</prism:startingPage>
<prism:endingPage>889</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/890?rss=1">
<title><![CDATA[The distinct ophthalmic phenotype of Knobloch syndrome in children]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/890?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Knobloch syndrome is defined as a triad of occipital defect, high myopia and vitreo-retinal degeneration (often with later retinal detachment); however, the ocular phenotype is not well defined. This report characterises eye findings of the syndrome in children with genetically confirmed disease.</p>
</sec>
<sec><st>Methods</st>
<p>Case series of Saudi children with previously documented homozygous mutations in <I>COL18A1</I> or <I>ADAMTS18</I>.</p>
</sec>
<sec><st>Results</st>
<p>All eight children (4&ndash;15&nbsp;years old; five families) had smooth (cryptless) irides, high myopia (&ndash;10 to &ndash;20 dioptres) and distinctive vitreo-retinal degeneration consisting of diffuse very severe retinal pigment epithelium atrophic changes with prominent choroidal vessel show, macular atrophic lesions with or without a &lsquo;punched out&rsquo; appearance and white fibrillar vitreous condensations. In two probands and a sibling, this distinctive retinal appearance was the basis for initial clinical diagnosis. Six children had temporal ectopia lentis and four had posterior perinuclear lens opacity. Additional features included developmental delay (two), epilepsy (one) and heterotopic grey matter in the lateral ventricles (one). Four children had no clinically discernible occipital defect.</p>
</sec>
<sec><st>Conclusion</st>
<p>Taken together, smooth iridies, ectopia lentis and characteristic vitreo-retinal degeneration seem pathognomonic. Although it is a defining feature of the syndrome, clinically discernible occipital defect is not a <I>sine qua non</I> for the diagnosis. Ophthalmologists are uniquely able to diagnose Knobloch syndrome.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Khan, A. O., Aldahmesh, M. A., Mohamed, J. Y., Al-Mesfer, S., Alkuraya, F. S.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301396</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301396</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Paediatrics, Eye (globe), Lens and zonules, Optic nerve, Retina, Neurology, Optics and refraction]]></dc:subject>
<dc:title><![CDATA[The distinct ophthalmic phenotype of Knobloch syndrome in children]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>890</prism:startingPage>
<prism:endingPage>895</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/896?rss=1">
<title><![CDATA[Survey of systematic reviews and meta-analyses published in ophthalmology]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/896?rss=1</link>
<description><![CDATA[
<sec><st>Purpose</st>
<p>To analyse the types of systematic reviews and meta-analyses published in the field of ophthalmology.</p>
</sec>
<sec><st>Methods</st>
<p>The systematic reviews and meta-analysis in ophthalmology published in peer-reviewed journals were retrieved. The distribution of systematic reviews and meta-analyses in various ophthalmic subspecialties, type of study and country of origin were determined.</p>
</sec>
<sec><st>Results</st>
<p>A total of 533 records were identified as systematic reviews and meta-analysis in ophthalmology. Overall, retina and glaucoma were the two major subspecialties accounting for 35% and 21% of the published systematic reviews and meta-analyses, respectively. The major topics published in retina were age-related macular degeneration (37%), tumours (14%), and diabetic retinopathy (12%). More than half (56%) the systematic reviews and meta-analyses were interventional. The author affiliations of these studies were largely from the USA (30%) and the UK (22%). About 60% of the systematic reviews and meta-analyses were published in ophthalmology journals, followed by the Cochrane Library (15.75%) and other non-ophthalmic journals (25.14%), respectively. The number of publications increased from 3 per year in 1994 to almost 100 per year in 2010.</p>
</sec>
<sec><st>Conclusions</st>
<p>The number of published systematic reviews and meta-analyses has been increasing progressively over the past few years. Retina and glaucoma are the two most commonly published topics. Non-ophthalmology journals form a sizeable proportion of avenues for ophthalmic publications.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Chen, H., Jhanji, V.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301589</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301589</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Angle, Intraocular pressure, Retina, Glaucoma]]></dc:subject>
<dc:title><![CDATA[Survey of systematic reviews and meta-analyses published in ophthalmology]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Clinical science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>896</prism:startingPage>
<prism:endingPage>899</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/900?rss=1">
<title><![CDATA[Aged peripheral retinal lesions originating from the ciliary body sweep away the retinal pigmented epithelium]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/900?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>To investigate age-related lesions in the far-anterior retina that migrate from the ciliary body (CB) and how they affect the neural retina and retinal pigmented epithelium (RPE).</p>
</sec>
<sec><st>Methods</st>
<p>One eye from three healthy subjects aged 87, 92 and 93&nbsp;years were used. Retinae were photographed, embedded in resin and then sectioned at 2&nbsp;&mu;m.</p>
</sec>
<sec><st>Results</st>
<p>Multiple elliptically shaped lesions were present in the CB. Larger lesions extended into the peripheral retina. Lesions resulted from deposits that had lenticular qualities. These develop centrally along Bruch's membrane sweeping away the RPE, such that piles of RPE cells were present around the deposits that resulted in retinal atrophy. The internal composition of the deposits revealed large numbers of spherical bodies, unlike those seen in drusen. RPE cells adjacent to these deposits and their underlying lesions became highly irregular, with melanin granules spacing themselves out within the cell and adopting similar orientations. This is a highly distinctive feature.</p>
</sec>
<sec><st>Conclusions</st>
<p>These far-anterior deposits were different in nature from drusen in terms of morphology, composition and origin. They swept away the RPE, exposing the Bruch's membrane and isolating the retina, leading to atrophy. They appeared to originate from the CB and progressed centrally. The deposits may have developed from the ciliary muscle, which would account for their elongated orientation. Their impact on melanin distribution in RPE cells was unexpected and unusual, implying that they release a signal that influences melanin organisation.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Begum, R., Jeffery, G.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301273</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301273</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Unlocked]]></dc:subject>
<dc:title><![CDATA[Aged peripheral retinal lesions originating from the ciliary body sweep away the retinal pigmented epithelium]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Laboratory science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>900</prism:startingPage>
<prism:endingPage>904</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/905?rss=1">
<title><![CDATA[Toxicity of voriconazole on corneal endothelial cells in an animal model]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/905?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>To determine the effect of intracamerally injected voriconazole on corneal endothelial cells in rabbit eyes.</p>
</sec>
<sec><st>Methods</st>
<p>Various concentrations of voriconazole (0%, 0.03%, 0.1%, 0.25%, 0.5% and 1%) were injected intracamerally in 36 eyes of 18 rabbits (six eyes for each concentration). Measurements of endothelial cell counts and central corneal thickness were performed at 30, 60, 90 and 120&nbsp;min after the injection. In each group, five of six corneas were used for the live/dead cell assay; staining with alizarin red and trypan was done. In one cornea from each group, scanning electron microscopy was performed.</p>
</sec>
<sec><st>Results</st>
<p>There was no significant difference in endothelial cell counts and central corneal thickness among the six groups at any time points. The live/dead cell assay revealed no difference in the mean percentage of dead endothelial cells among the six groups (p=0.504). However, scanning electron microscopy revealed blurring of cell border at voriconazole concentrations &ge;0.25%, indicating cell wall damage.</p>
</sec>
<sec><st>Conclusion</st>
<p>Intracameral injection of voriconazole did not induce a significant gross change in rabbit corneal endothelial cells up to a concentration of 1%. However, risk of microstructural damages might exist with a concentration of &ge;0.25%.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Han, S. B., Yang, H. K., Hyon, J. Y., Shin, Y. J., Wee, W. R.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301129</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301129</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Toxicity of voriconazole on corneal endothelial cells in an animal model]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Original articles - Laboratory science</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>905</prism:startingPage>
<prism:endingPage>908</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/909?rss=1">
<title><![CDATA[Acute episode of eyelid oedema]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/909?rss=1</link>
<description><![CDATA[ <p>A 34-year-old Caucasian man presented to the ophthalmology emergency clinic with painless, bilateral upper and lower eyelid oedema since waking up that morning. The patient denied any history of lip swelling, tongue swelling, or shortness of breath. He reported a recent episode of an upper respiratory infection that had resolved. He was otherwise in good health. Medications included cetirizine HCl 10&nbsp;mg a day and guaifenesin 1200&nbsp;mg twice a day. He denied allergies to medications. Family history was negative for skin disease or angioedema.</p> <p>Further history revealed that the patient had recurrent episodes of eyelid oedema from the age of 10&nbsp;years, each lasting 5&ndash;7&nbsp;days and with a frequency of two to five episodes per year. All episodes were associated with antecedent upper respiratory infection. The patient reported that each episode progressed similarly with spontaneous onset of bilateral, upper and lower eyelid swelling and conjunctival injection followed by irritation, foreign body...]]></description>
<dc:creator><![CDATA[Hallahan, K. M., Sood, A., Singh, A. D.]]></dc:creator>
<dc:date>2012-05-15T13:21:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-301460</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-301460</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Paediatrics, Vision, Neurology]]></dc:subject>
<dc:title><![CDATA[Acute episode of eyelid oedema]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Education</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>909</prism:startingPage>
<prism:endingPage>909</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/910-a?rss=1">
<title><![CDATA[Comment on: The role of the optical coherence tomography in identifying shape and size of idiopathic epiretinal membranes]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/910-a?rss=1</link>
<description><![CDATA[ <p>We read with great interest the paper by Hajnajeeb <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> about the role of optical coherence tomography in identifying the shape and size of idiopathic epiretinal membranes (ERM). We have some concerns and comments about the study.</p> <p>Although the authors stated the investigators were blinded to image analyses, it is not possible for several reasons. First, the colour-coded retinal thickness map (RTM) image has several different colours representing different thickness levels, but the intraoperative image has only two; stained and unstained. Second, the RTM images may have some island regarding the thickness level as seen in figure 1, but the intraoperative pictures have diffuse content. Third, colour-coded RTM images are interpolated from the measured retinal thickness from the 128 B scan (each containing 512 A scans) optic coherence tomography (OCT) images. Therefore, these interpolation leads soften the interval zones. According to the reasons stated above, someone...]]></description>
<dc:creator><![CDATA[Ayata, A., Yildirim, Y.]]></dc:creator>
<dc:date>2012-05-15T13:21:39-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301659</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301659</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Comment on: The role of the optical coherence tomography in identifying shape and size of idiopathic epiretinal membranes]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Letters</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>910</prism:startingPage>
<prism:endingPage>910</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/910-b?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/910-b?rss=1</link>
<description><![CDATA[ <p>We would like to thank Dr Ayata and colleagues<cross-ref type="bib" refid="b1">1</cross-ref> for their interest in our work<cross-ref type="bib" refid="b2">2</cross-ref> and their comments and concerns regarding our publication.<l type="ord"><li><p>Throughout our manuscript, we did not mention that our study was blinded. In contrast, we clearly referred in both the methods and the discussion sections that our work was not blinded giving the explanation for that decision (eg, Discussion: &lsquo;...and the non-blinded form of our study have to be considered.&rsquo;).</p> </li><li> <p>We fully agree with Dr Ayata and colleagues regarding the inappropriate usage of &mu;m<sup>2</sup> instead of mm<sup>2</sup> unit and thank them for the notification.</p> </li><li> <p>We agree with Dr Ayata and colleagues that retinal thickness map is not a real image and some software in the modern optical coherence tomography equipment possibly gives better assessment of the size and shape of the epiretinal membrane (ERM). On the other hand, as we...]]></description>
<dc:creator><![CDATA[Hajnajeeb, B., Georgopoulos, M., Sayegh, R., Geitzenauer, W., Schmidt-Erfurth, U. M.]]></dc:creator>
<dc:date>2012-05-15T13:21:39-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2012-301765</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2012-301765</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Letters</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>910</prism:startingPage>
<prism:endingPage>911</prism:endingPage>
</item>
<item rdf:about="http://bjo.bmj.com/cgi/content/short/96/6/911?rss=1">
<title><![CDATA[Evaluation of three PCR assays for the detection of fungi in patients with mycotic keratitis]]></title>
<link>http://bjo.bmj.com/cgi/content/short/96/6/911?rss=1</link>
<description><![CDATA[ <p>Mycotic keratitis is a leading cause of ocular morbidity throughout the world and a higher incidence of fungal keratitis has been reported from tropical and subtropical countries. Early diagnosis is important for the prompt management of this disorder. Among the various diagnostic tests available, culture is considered the gold standard. The other commonly used techniques include direct microscopic examination methods like potassium hydroxide with or without calcofluor white wet mount, Grams stain, acridine orange and Giemsa stain.<cross-ref type="bib" refid="b1">1</cross-ref> In the face of a negative culture, microscopy is relied upon for initiation of antifungal therapy.<cross-ref type="bib" refid="b2">2</cross-ref> While the culture of fungus from clinical samples requires 2&nbsp;days to 2&nbsp;weeks, the positive culture rate may be influenced by prior antifungal therapy and the number of organisms present in the clinical samples.<cross-ref type="bib" refid="b3">3</cross-ref></p> <p>The PCR assays targeting several regions on fungal ribosomal DNA have been evaluated separately for the detection...]]></description>
<dc:creator><![CDATA[Balne, P. K., Reddy, A. K., Kodiganti, M., Gorli, S. R., Garg, P.]]></dc:creator>
<dc:date>2012-05-15T13:21:39-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bjophthalmol-2011-300207</dc:identifier>
<dc:identifier>hwp:master-id:bjophthalmol;bjophthalmol-2011-300207</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Evaluation of three PCR assays for the detection of fungi in patients with mycotic keratitis]]></dc:title>
<prism:publicationDate>2012-06-01</prism:publicationDate>
<prism:section>Letters</prism:section>
<prism:volume>96</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>911</prism:startingPage>
<prism:endingPage>912</prism:endingPage>
</item>
</rdf:RDF>
